Journal of Heart and Lung Transplantation

Journal

Publication Venue For

  • IL-33 mediates Pseudomonas induced airway fibrogenesis and is associated with CLAD.  42:53-63. 2023
  • Contemporary trends in PGD incidence, outcomes, and therapies.  41:1839-1849. 2022
  • Racial and socioeconomic disparities in pediatric heart transplant outcomes in the era of anti-thymocyte globulin induction.  41:1773-1780. 2022
  • ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery.  41:1135-1194. 2022
  • Practice variation in the diagnosis of acute rejection among pediatric heart transplant centers: An analysis of the pediatric heart transplant society (PHTS) registry.  40:1550-1559. 2021
  • N-myc-interactor mediates microbiome induced epithelial to mesenchymal transition and is associated with chronic lung allograft dysfunction.  40:447-457. 2021
  • Risk of primary graft dysfunction following lung transplantation in selected adults with connective tissue disease-associated interstitial lung disease.  40:351-358. 2021
  • Pregnancy after heart transplantation: A second-generation transmission of the gift of life—in reply.  40:235. 2021
  • International Society for Heart and Lung Transplantation consensus statement for the standardization of bronchoalveolar lavage in lung transplantation.  39:1171-1190. 2020
  • Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation: An IMACS analysis.  39:904-914. 2020
  • A current era analysis of ABO incompatible listing practice and impact on outcomes in young children requiring heart transplantation.  39:627-635. 2020
  • Center and Donor Factors Associated with Discrepant Responses to Donor Lung Offers.  39:S140. 2020
  • Clinical Characteristics and Outcomes of Patients Requiring Prolonged Inotropes after Left Ventricular Assist Device Implantation.  39:S445-S446. 2020
  • Combined Thoracic-Kidney Transplantation Practices May Exacerbate Existing Geographic Disparities in Access to Deceased Donor Kidney Transplantation.  39:S366-S367. 2020
  • Gender Differences in Early Mortality after LVAD: An IMACS Analysis.  39:S108. 2020
  • Health-Related Quality of Life Differs by Pre-Operative Implant Strategy from before through Mid-Term after Surgery: Findings from INTERMACS.  39:S208. 2020
  • Implications of ECMO Bridging and Salvage Strategies on Mortality and PGD.  39:S103-S104. 2020
  • Incidence and Onset of Leukopenia in Adults the First Year after Orthotopic Heart Transplantation.  39:S274. 2020
  • Multi-Center Validation of a Consensus-Based Scoring Guide for Evaluating Donor Lung Offers.  39:S216. 2020
  • Persistent Mitral Regurgitation after Left Ventricular Assist Device: A Clinical Conundrum.  39:S402. 2020
  • Short- and long-term adverse events in patients on temporary circulatory support before durable ventricular assist device: An IMACS registry analysis.  39:342-352. 2020
  • The Cost and Length of Stay Associated with Biventricular Assist Devices in the United States (2009-2015).  39:S400-S401. 2020
  • The Fontan Liver after Cardiac Transplantation.  39:S67. 2020
  • True, maybe true, perhaps unrelated – granulocyte colony-stimulating factor and increased risk of rejection in heart transplant recipients.  39:403. 2020
  • American Association for Thoracic Surgery/International Society for Heart and Lung Transplantation guidelines on selected topics in mechanical circulatory support.  39:187-219. 2020
  • Longitudinal impact of temporary mechanical circulatory support on durable ventricular assist device outcomes: An IMACS registry propensity matched analysis.  39:145-156. 2020
  • Pathological insights into persistent mitral regurgitation following continuous flow left ventricular assist device implantation.  39:184-186. 2020
  • Pregnancy outcomes in women with cardiothoracic transplants: A Systematic review and meta-analysis.  39:93-102. 2020
  • Differences in health-related quality of life by implant strategy: Analyses from the Interagency Registry for Mechanically Assisted Circulatory Support.  39:62-73. 2020
  • Blood pressure in a mechanically assisted circulation: “Heat, spirit, perfection”.  38:406-407. 2019
  • Epidemiology of infection in mechanical circulatory support: A global analysis from the ISHLT Mechanically Assisted Circulatory Support Registry.  38:364-373. 2019
  • Evaluation of flow-modulation approaches in ventricular assist devices using an in-vitro endothelial cell culture model.  38:456-465. 2019
  • Outcomes with ambulatory advanced heart failure from the Medical Arm of Mechanically Assisted Circulatory Support (MedaMACS) Registry.  38:408-417. 2019
  • Third Annual Report From the ISHLT Mechanically Assisted Circulatory Support Registry: A comparison of centrifugal and axial continuous-flow left ventricular assist devices.  38:352-363. 2019
  • Impact of body mass index on adverse events after implantation of left ventricular assist devices: An IMACS registry analysis.  37:1207-1217. 2018
  • Bloodstream infections in mechanical circulatory support device recipients in the International Society of Heart and Lung Transplantation Mechanically Assisted Circulation Support Registry: Epidemiology, risk factors, and mortality.  37:1013-1020. 2018
  • Second annual report from the ISHLT Mechanically Assisted Circulatory Support Registry.  37:685-691. 2018
  • Distal airway microbiome is associated with immunoregulatory myeloid cell responses in lung transplant recipients.  37:206-216. 2018
  • Practical application of gene expression arrays in a clinical setting: The light at the end of a long tunnel.  36:1178-1179. 2017
  • Report of the ISHLT Working Group on primary lung graft dysfunction Part IV: Prevention and treatment: A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation.  36:1121-1136. 2017
  • Characteristics of lung allocation score exception requests submitted to the national Lung Review Board.  36:812-814. 2017
  • Use of a novel pulmonary artery cannula to provide extracorporeal membrane oxygenation as a bridge to lung transplantation.  35:1051-1053. 2016
  • Evaluation of the effect of diminished pulsatility as seen in continuous flow ventricular assist devices on arterial endothelial cell phenotype and function.  35:930-932. 2016
  • Cardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure.  35:795-807. 2016
  • The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking and reperfusion hyperoxia.  35:500-507. 2016
  • Impact of initial Norwood shunt type on young hypoplastic left heart syndrome patients listed for heart transplant: A multi-institutional study.  35:301-305. 2016
  • Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold.  34:1198-1207. 2015
  • Exercise physiology, testing, and training in patients supported by a left ventricular assist device.  34:1005-1016. 2015
  • Pulmonary hypertension related to left heart disease: Insight from a wireless implantable hemodynamic monitor.  34:329-337. 2015
  • Adult cardiothoracic transplant nursing: An ISHLT consensus document on the current adult nursing practice in heart and lung transplantation.  34:139-148. 2015
  • Lung size mismatch and primary graft dysfunction after bilateral lung transplantation.  34:233-240. 2015
  • Have risk factors for mortality after heart transplantation changed over time? Insights from 19 years of Cardiac Transplant Research Database study.  33:1304-1311. 2014
  • A multi-institutional study of malignancies after heart transplantation and a comparison with the general United States population.  33:478-485. 2014
  • Cerebrovascular disease in the era of left ventricular assist devices with continuous flow: Risk factors, diagnosis, and treatment.  33:878-887. 2014
  • Single-center experience with extracorporeal photopheresis in pediatric heart transplantation.  33:624-628. 2014
  • Disparities in lung transplantation before and after introduction of the lung allocation score.  32:684-692. 2013
  • Factors associated with stress and coping at 5 and 10 years after heart transplantation.  32:437-446. 2013
  • Retransplantation as a successful therapy for post-transplant protein-losing enteropathy.  32:472-473. 2013
  • VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients.  32:120-128. 2013
  • Symptom burden, quality of life, and attitudes toward palliative care in patients with pulmonary arterial hypertension: Results from a cross-sectional patient survey.  31:1102-1108. 2012
  • A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation.  31:942-949. 2012
  • Rapidly progressive pulmonary venoocclusive disease in young women taking oral contraceptives.  31:1031-1036. 2012
  • Opportunities for improvement in heart transplantation outcomes for young adults 18 to 35 years of age.  31:903-904. 2012
  • 116 Gastrointestinal Bleeding Risk in Patients with Ventricular Assist Devices.  31:s47-s48. 2012
  • Comparison of risk factors and outcomes for pediatric patients listed for heart transplantation after bidirectional Glenn and after Fontan: An analysis from the Pediatric Heart Transplant Study.  31:133-139. 2012
  • Use of sublingual tacrolimus in lung transplant recipients.  31:127-132. 2012
  • Older patients (age 65+) report better quality of life, psychological adjustment, and adherence than younger patients 5 years after heart transplant: A multisite study.  31:478-484. 2012
  • Allosensitization and outcomes in pediatric heart transplantation.  30:1221-1227. 2011
  • Improvement in 2-year survival for ventricular assist device patients after implementation of an intensive surveillance protocol.  30:879-887. 2011
  • The role of fibrinolytic genes and proteins in the development of allograft vascular disease.  30:935-944. 2011
  • Report from a consensus conference on antibody-mediated rejection in heart transplantation.  30:252-269. 2011
  • Minimizing infection and rejection death: Clues acquired from 19 years of multi-institutional cardiac transplantation data.  30:151-157. 2011
  • Mitral valve prolapse after long-term mechanical ventricular unloading.  30:1067-1068. 2011
  • Construct validity of the definition of primary graft dysfunction after lung transplantation.  29:1231-1239. 2010
  • Balancing rejection and infection with respect to age, race, and gender: Clues acquired from 17 years of cardiac transplantation data.  29:966-972. 2010
  • Clinical management of continuous-flow left ventricular assist devices in advanced heart failure.  29:1081. 2010
  • On solid-phase antibody assays.  29:1207-1209. 2010
  • Pandemic influenza (H1N1): Impact on lung transplant recipients and candidates.  29:1034-1038. 2010
  • Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients.  29:1009-1013. 2010
  • Outcomes of Pediatric Patients With Hypertrophic Cardiomyopathy Listed for Transplant.  28:1329-1334. 2009
  • Transforming Growth Factor-beta Polymorphisms and Cardiac Allograft Rejection.  28:1057-1062. 2009
  • Symptom Frequency and Distress from 5 to 10 Years After Heart Transplantation.  28:759-768. 2009
  • Safety and Efficacy of Ibutilide in Heart Transplant Recipients.  28:505-507. 2009
  • The 15-Step Oximetry Test: a Reliable Tool to Identify Candidates for Lung Transplantation Among Patients With Idiopathic Pulmonary Fibrosis.  28:328-333. 2009
  • Report From a Consensus Conference on the Sensitized Patient Awaiting Heart Transplantation.  28:213-225. 2009
  • Intraoperative Evaluation of the HeartMate II Flow Estimator.  28:39-43. 2009
  • Human, Bovine and Porcine Systematic Vascular Input Impedances Are Not Equivalent: Implications for Device Testing and Xenotransplantation in Heart Failure.  27:1340-1347. 2008
  • Patient With Hypofibrinolysis-mediated Thromboembolism Converted to a Hypercoagulable/Hyperfibrinolytic State via Ventricular Assist Device Placement.  27:1169-1171. 2008
  • Amiodarone Pulmonary Toxicity After Lung Transplantation.  27:1059-1063. 2008
  • Continuous Hemodynamic Monitoring in Patients With Pulmonary Arterial Hypertension.  27:780-788. 2008
  • Re-stenosis After Drug-eluting Stents in Cardiac Allograft Vasculopathy.  27:610-615. 2008
  • Use of an Intraperitoneal Ventricular Assist Device With a Polytetrafluoroethylene Barrier Decreases Infections.  27:268-271. 2008
  • Role for CD4+CD25+ T Cells in Inhibition of Graft Rejection by Extracorporeal Photopheresis.  27:616-622. 2008
  • Fatal Diffuse Alveolar Damage in Two Lung Transplant Patients Treated With Cetuximab.  26:1340-1344. 2007
  • Patterns and Predictors of Physical Functional Disability at 5 to 10 Years After Heart Transplantation.  26:1182-1191. 2007
  • Alterations in the Fibrinolytic Cascade Post-transplant: Evidence of a Bimodal Expression Pattern.  26:494-497. 2007
  • Patterns and Predictors of Quality of Life at 5 to 10 Years After Heart Transplantation.  26:535-543. 2007
  • A Wireless Pressure Sensor for Monitoring Pulmonary Artery Pressure in Advanced Heart Failure: Initial Experience.  26:85-88. 2007
  • Acute take-off of the right coronary artery with long intra-aortic wall course presenting as chronic coronary ostium occlusion in a patient with end-stage heart failure.  25:740-742. 2006
  • Argatroban, Bivalirudin, and Lepirudin do not Decrease Clot Propagation and Strength as Effectively as Heparin-activated Antithrombin In Vitro.  25:653-663. 2006
  • Improving clinical practice: Should we give influenza vaccinations to heart transplant patients?.  25:320-323. 2006
  • Rejection with hemodynamic compromise: Objective evidence for efficacy of photopheresis.  25:283-288. 2006
  • Should status II patients be removed from the pediatric heart transplant waiting list? A multi-institutional study.  25:271-275. 2006
  • Heart Rhythm Considerations in Heart Transplant Candidates and Considerations for Ventricular Assist Devices: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates-2006.  25:1043-1056. 2006
  • Predictors of physical functional disability at 5 to 6 years after heart transplantation.  24:2279-2285. 2005
  • Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.  24:2196-2201. 2005
  • Who returns to work after heart transplantation?.  24:2255-2261. 2005
  • Multi-organ transplantation: Is there a protective effect against acute and chronic rejection?.  24:1828-1833. 2005
  • The intensive care unit oxygen challenge should not be used for donor lung function decision-making.  24:1902-1905. 2005
  • Post-operative obesity and cachexia are risk factors for morbidity and mortality after heart transplant: Multi-institutional study of post-operative weight change.  24:1424-1430. 2005
  • Predictors of quality of life at 5 to 6 years after heart transplantation.  24:1431-1439. 2005
  • Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.  24:517-525. 2005
  • Of mice and men: Mouse models and the molecular mechanisms of post-transplant coronary artery disease.  24:2003-2014. 2005
  • Re-stenosis of a sirolimus-coated stent in a heart transplant recipient with allograft vasculopathy.  24:1444.e9-1444.e11. 2005
  • The case for selective re-issuance of medical certificates to allow pilots who have received a heart transplant to resume flying.  24:259-269. 2005
  • To induce or not to induce: Do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy?.  24:392-400. 2005
  • Use of bivalirudin, a direct thrombin inhibitor, and its reversal with modified ultrafiltration during heart transplantation in a patient with heparin-induced thrombocytopenia.  24:222-225. 2005
  • Standardized guidelines for surveillance bronchoscopy reduce complications in lung transplant recipients.  23:110-114. 2004
  • Retransplantation in 7,290 primary transplant patients: A 10-year multi-institutional study.  22:862-868. 2003
  • Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease.  22:515-518. 2003
  • Change in quality of life from before to after discharge following left ventricular assist device implantation.  22:322-333. 2003
  • Change in quality of life from after left ventricular assist device implantation to after heart transplantation.  22:1254-1267. 2003
  • Aortic graft transplantation in mice.  21:1319-1321. 2002
  • PG490-88, a derivative of triptolide, attenuates obliterative airway disease in a mouse heterotopic tracheal allograft model.  21:1314-1318. 2002
  • Mechanical circulatory support for myocarditis: How much recovery should occur before device removal?.  21:1246-1249. 2002
  • Cardiac transplant patients response to the 31P MRS stress test.  21:522-529. 2002
  • Indefinite allograft survival mediated by donor bone marrow is dependent on the presence of a functional CD95 (Fas) gene in recipients.  20:1132-1135. 2001
  • Peter Medawar and the science of transplantation: A parable.  20:927. 2001
  • Cardiomyopathy in a carrier of Duchenne's muscular dystrophy.  20:781-784. 2001
  • Improvement in quality of life outcomes 2 weeks after left ventricular assist device implantation.  20:657-669. 2001
  • Cardiac transplant outcome of patients supported on left ventricular assist device vs intravenous inotropic therapy.  20:449-456. 2001
  • A multi-institutional study of cardiac retransplantation: incidence, risk factors for mortality, and outcome..  20:181. 2001
  • Differential modulation of alloreactive T cell receptor expression induced by allogeneic bone marrow and splenocyte infusions..  20:172. 2001
  • The emergence of co-morbid diseases impacting survival after cardiac transplantation, a ten year multi-institutional experience..  20:167-168. 2001
  • Who is most likely to enjoy long term survival after cardiac transplantation? Risk stratification in a 10 year multi-institutional experience..  20:168-169. 2001
  • The utility of open lung biopsy following lung transplantation.  19:852-857. 2000
  • Activities of daily living among heart transplant candidates: Neuropsychological and cardiac function predictors.  19:995-1006. 2000
  • Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: A multi-institutional study of preoperative weight-height indices.  18:750-763. 1999
  • Donor management, organ preservation, organ distribution coronary endothelial dysfunction of isolated hearts subjected to prolonged cold storage: Patterns and contributing factors.  18:239-247. 1999
  • Predictors of quality of life in patients at one year after heart transplantation.  18:202-210. 1999
  • Protective effects of Celsior in lung transplantation.  18:320-327. 1999
  • Heart transplant coronary artery disease detected by coronary angiography: A multiinstitutional study of preoperative donor and recipient risk factors.  17:744-753. 1998
  • Heart transplant coronary artery disease detected by coronary angiography: a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database..  17:744-753. 1998
  • Patient compliance at one year and two years after heart transplantation.  17:383-394. 1998
  • Risk of death or incapacitation after heart transplantation, with particular reference to pilots.  17:497-504. 1998
  • Infection after pediatric heart transplantation: Results of a multiinstitutional study.  16:1207-1215. 1997
  • Serial measurements of interleukin-6, interleukin-8, tumor necrosis factor-α, and soluble vascular cell adhesion molecule-1 in the peripheral blood plasma of human cardiac allograft recipients.  16:1046-1053. 1997
  • Heart transplant rejection with hemodynamic compromise: A multiinstitutional study of the role of endomyocardial cellular infiltrate.  16:813-821. 1997
  • The incremental risk of female sex in heart transplantation: A multiinstitutional study of peripartum cardiomyopathy and pregnancy.  16:801-812. 1997
  • Symptom distress three months after heart transplantation.  16:604-614. 1997
  • Heart transplant rejection with hemodynamic compromise: a multiinstitutional study of the role of endomyocardial cellular infiltrate. Cardiac Transplant Research Database..  16:813-821. 1997
  • The incremental risk of female sex in heart transplantation: a multiinstitutional study of peripartum cardiomyopathy and pregnancy. Cardiac Transplant Research Database Group..  16:801-812. 1997
  • Competing outcomes after heart transplantation: A comparison of eras and outcomes.  16:190-198. 1997
  • Improvement in quality of life in patients with heart failure who undergo transplantation.  15:749-757. 1996
  • Impact of the heart transplant waiting process on spouses.  15:623-630. 1996
  • Poststorage diastolic abnormalities of heart transplants: Is vascular dysfunction or myocardial contracture the culprit?.  15:461-469. 1996
  • Risk factors for early, cumulative, and fatal infections after heart transplantation: A multiinstitutional study.  15:329-341. 1996
  • Semiquantitative measurement of cytokine messenger RNA in endomyocardium and peripheral blood mononuclear cells from human heart transplant recipients.  15:206-217. 1996
  • Evaluation of a new preservation solution: Celsior in the isolated rat lung.  14:601-604. 1995
  • The high risk heart donor: Potential pitfalls.  14:424-428. 1995
  • Evaluation of a new preservation solution: Celsior in the isolated rat lung. Paris-Sud University Lung Transplatation Group..  14:601-604. 1995
  • Predictors of quality of life in patients with advanced heart failure awaiting transplantation.  14:2-10. 1995
  • Predictors of quality of life in patients with advanced heart failure awaiting transplantation..  14:2-10. 1995
  • Risk factors for late recurrent rejection after heart transplantation: A multiinstitutional, multivariable analysis.  14:409-418. 1995
  • Risk factors for late recurrent rejection after heart transplantation: a multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group..  14:409-418. 1995
  • Utility of posttransplantation panel-reactive antibody measurements for the prediction of rejection frequency and survival of heart transplant recipients.  14:856-864. 1995
  • Monitoring of acute lung rejection and infection by bronchoalveolar lavage and plasma levels of hyaluronic acid in clinical lung transplantation.  13:958-962. 1994
  • Treatment of recurrent heart rejection with mycophenolate mofetil (RS- 61443): Initial clinical experience.  13:444-450. 1994
  • Cytomegalovirus after heart transplantation. Risk factors for infection and death: A multiinstitutional study.  13:394-404. 1994
  • Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group..  13:394-404. 1994
  • Infection after heart transplantation: A multiinstitutional study.  13:381-393. 1994
  • Infection after heart transplantation: a multiinstitutional study. Cardiac Transplant Research Database Group..  13:381-392. 1994
  • Influence of HLA mismatch on rejection after heart transplantation: A multiinstitutional study.  13:583-596. 1994
  • Influence of HLA mismatch on rejection after heart transplantation: a multiinstitutional study. The Cardiac Transplant Research Database Group..  13:583-595. 1994
  • Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: A multivariable, multiinstitutional report.  13:353-365. 1994
  • Matching the heart donor and heart transplant recipient. Clues for successful expansion of the donor pool: a multivariable, multiinstitutional report. The Cardiac Transplant Research Database Group..  13:353-364. 1994
  • Efficacy of lactobionate-enriched cardioplegic solution in preserving compliance of cold-stored heart transplants.  12:1053-1061. 1993
  • Efficacy of lactobionate-enriched cardioplegic solution in preserving compliance of cold-stored heart transplants..  12:1053-1061. 1993
  • Pretransplantation risk factors for acute rejection after heart transplantation: A multiinstitutional study.  12:355-366. 1993
  • Pretransplantation risk factors for acute rejection after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group..  12:355-366. 1993
  • Pretransplantation risk factors for death after heart transplantation: A multiinstitutional study.  12:549-562. 1993
  • Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. The Transplant Cardiologists Research Database Group..  12:549-562. 1993
  • Total lymphoid irradiation: is there a role in pediatric heart transplantation?.  12:S293-S300. 1993
  • Methotrexate pulse therapy in the treatment of recurrent acute heart rejection.  11:1116-1124. 1992
  • Cyclosporine blood monitoring after heart transplantation: A prospective comparison of monoclonal and polyclonal radioimmunoassays.  11:522-529. 1992
  • Cyclosporine blood monitoring after heart transplantation: a prospective comparison of monoclonal and polyclonal radioimmunoassays..  11:522-529. 1992
  • Distinguishing between infection, rejection, and the adult respiratory distress syndrome after human lung transplantation.  11. 1992
  • Distinguishing between infection, rejection, and the adult respiratory distress syndrome after human lung transplantation..  11:S232-S236. 1992
  • Donor cerebral emboli as a cause of acute graft dysfunction in lung transplantation.  11:72-76. 1992
  • Donor cerebral emboli as a cause of acute graft dysfunction in lung transplantation..  11:72-76. 1992
  • Renal, hemodynamic, and electrocardiographic effects of low versus high osmolality contrast agents on the transplanted heart.  11:584-586. 1992
  • Renal, hemodynamic, and electrocardiographic effects of low versus high osmolality contrast agents on the transplanted heart..  11:584-586. 1992
  • Total lymphoid irradiation in the treatment of early or recurrent heart rejection.  11:902-912. 1992
  • Pulmonary vascular resistance and the risk of heart transplantation.  7:331-336. 1988
  • International Standard Serial Number (issn)

  • 0887-2570
  • 1053-2498
  • Electronic International Standard Serial Number (eissn)

  • 1557-3117